OC
GALT icon

Oarsman Capital’s Galectin Therapeutics GALT Stock Holding History

Oarsman Capital’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,698
Closed -$12.5K – 471
2024
Q4 		$12.5K Hold
9,698
– – ﹤0.01% 665
2024
Q3 		$26.7K Buy
+9,698
New +$23.8K ﹤0.01% 556

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Oarsman Capital's GALT Position: Q1 2025 in Review

Oarsman Capital sold out of Galectin Therapeutics (GALT) in Q1 2025, closing a stake of 9,698 shares — an estimated $12.5K sold.

Oarsman Capital first reported a position in GALT in Q3 2024 and held it in 2 quarters. The position peaked at $26.7K in Q3 2024. 93 funds tracked by Wall St. Rank hold GALT as of Q1 2025.

  • Oarsman Capital reported no remaining Galectin Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Oarsman Capital sold 9,698 Galectin Therapeutics shares in Q1 2025, an estimated $12.5K.
  • Oarsman Capital first reported a position in Galectin Therapeutics in Q3 2024 and held it in 2 quarters.
  • Oarsman Capital's Galectin Therapeutics position peaked at $26.7K in Q3 2024.
  • 93 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2025.

Based on Oarsman Capital's 13F filing for Q1 2025, filed 14 May 2025.